Undoubtedly, the existence of and first clinical data for an FDA-approved BTK inhibitor, ibrutinib (also known as PCI-32765), in oncology (8) make preclinical and translational research into BTK’s innate functions highly interesting, for example in arthritis (30), thromboinflammation (51), or in ischemic stroke, as aforementioned (52, 54). This evidence concerns the gene BTK and ischemic stroke.